QUOTE AND NEWS
Marketwire  Jan 27  Comment 
YOKNEAM, ISRAEL -- (Marketwire) -- 01/27/10 -- Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company and innovator in the development, marketing and sales of elos™ combined-energy medical aesthetic devices and other laser
Globe Newswire  Jan 5  Comment 
BURLINGTON, Mass., Jan. 5, 2010 (GLOBE NEWSWIRE) -- Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, announced today that its patent infringement lawsuits against
PR Newswire  Dec 15  Comment 
IRVINE, Calif., Dec. 15 /PRNewswire/ -- Syneron(TM) Medical Ltd. (Nasdaq: ELOS), http://www.syneron.com, an innovator in the development, marketing and sales of elos(TM) combined-energy medical aesthetic devices, today launches the "Make Me the
market folly  Dec 9  Comment 
In an amended 13G just filed with the SEC, Seth Klarman's hedge fund Baupost Group has disclosed a 5.45% ownership stake in Syneron Medical (ELOS). The filing was made due to activity on November 30th, 2009 and they now hold 1,500,000 shares. ...
Motley Fool  Dec 2  Comment 
Check out these highly rated stocks that have had a big price cut in the past month.
Stock Blog Hub  Nov 14  Comment 
Syneron Medical Ltd. (ELOS) announced the commercial launch of the elure topical skin whitening products in several Asian markets. The company will sell these products through its dermatologists, beauty salons and spas in Asia from the first...
Marketwire  Nov 11  Comment 
HONG KONG -- (Marketwire) -- 11/11/09 -- Syneron Medical Ltd. (NASDAQ: ELOS), an innovator in the development, marketing and sales of elos(TM) combined-energy medical aesthetic devices, today announced the commercial launch of the elure(TM) topical
StreetInsider.com  Nov 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Syneron+Medical+%28ELOS%29+Posts+Q3+Loss+of+20c%2C+Misses+Views+by+5c/5086519.html for the full story.
Marketwire  Nov 9  Comment 
YOKNEAM, ISRAEL -- (Marketwire) -- 11/09/09 -- Syneron Medical Ltd. (NASDAQ: ELOS) Recent highlights -- Third consecutive quarter of gross margin improvement -- Return to positive cash flow from operating activities during the three-month period



Thank you for your suggestion


 
TOP CONTRIBUTORS
Syneron (NASDAQ: ELOS), is recognized as a worldwide technology leader in the competitive medical aesthetics market. Syneron is now setting new industry standards for safety and efficacy for a wide range of medical-aesthetic procedures. Founded in 2000, Syneron has attained an unparalleled position in the aesthetics industry through science, synergy, and success.

Fundamentals

Revenue

Syneron earns most of its revenue from the sales of non-invasive electro-optical devices for treatment of cellulite, acne, wrinkles, vascular issues, and hair removal. Revenue is also earned by servicing existing Syneron devices. This service revenue accounted for 6.2% total revenue in 2006, and is expected to increase as more units are sold and installed.

As of November 2007, its worldwide sales breakdown was:

North America 52%
Asia 15%
Europe 28%
Other 5%

As of 2007, Syneron sells its products in 46 countries.

Market share/penetration

As of May 31, 2007, Syneron had a installed base of over 6,700 products.

Marketing is mainly targeted to dermatologists, plastic surgeons and other cosmetic physicians in North America and medical and non-medical practitioners outside North America. Furthermore, in North America, Syneron also focuses on primary-care physicians, ob-gyns, and other specialists offering aesthetic medical treatments.

Products

All of Syneron's products relate to its focus on non-invasive electro-optical devices for aesthetic treatments. These devices use both optical and radiofrequency (RF) energy. The addition of the RF energy allows for greater skin penetration of the desired effects.

eMax - Applications in skin tightening, skin rejuvenation, acne treatment, hair removal, and treatment of superficial vascular lesions.

eLight - Applications in facial skin tightening, skin rejuvenation, acne treatment, and hair removal.

eLaser - Applications in fractional skin treatment, hair removal and treatment of superficial vascular lesions.

VelaShape - Applications in temporary thigh circumferential reduction.

VelaSmooth - Applications in cellulite reduction.

Libra - Applications in microdermabrasion.

Synercool - Applications in cooling treated skin areas for improved comfort.

Pertinent Syneron Issues

elos technology

Syneron bases their devices on their patented elos technology. This technology utilizes both optical and radiofrequency (RF) energy, as opposed to the conventional purely-optical devices sold by many other device companies. Syneron claims that the addition of RF allows for greater skin penetration and better, and safer targeting of skin to be treated.

In practice, optical energy is initially used to heat the target area and make it more penetrable to RF energy. The RF is then used, which is more effective on the preheated areas, allowing for high specificity during the treatment process.

Israeli Company

Since it is an Israeli company and operates as an "Approved Enterprise", Syneron pays little/no corporate income tax. This tax benefit is set to expire in 2014.

Proctor and Gamble deal

Syneron has an agreement with Proctor and Gamble to market a home-based skin treatment system with applications in the treatment of fine lines, wrinkles, age and sun spots, and cellulite. Under the agreement, Syneron will handle the R&D and manufacturing, while Proctor and Gamble will focus on marketing and distribution. It is expected that this product will launch in the latter half of 2009.

Cellulite treatment

Currently, Syneron sells the only FDA-approved device for the reduction of the appearance of cellulite, through its VelaSmooth product line.

Industry Trends

Competition

The aesthetic devices market is currently very competitive, containing many companies with similar products. Competitors include Palomar Medical Technologies, Inc. (PMTI), Candela Corporation (CLZR), Cutera, Inc. (CUTR), Cynosure, Inc. (CYNO), IRIDEX Corporation (IRIX), Thermage, Inc. (THRM), and others. Currently, there is no clear market share leader among the aesthetic device companies.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki